Free Trial
NASDAQ:ATYR

aTyr Pharma Q2 2025 Earnings Report

aTyr Pharma logo
$5.30 +0.06 (+1.15%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$5.39 +0.09 (+1.70%)
As of 08/8/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.18
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

aTyr Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

aTyr Pharma Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

aTyr Pharma's Q3 2025 earnings is scheduled for Tuesday, August 12, 2025

aTyr Pharma Earnings Headlines

Is This Stock the 'Next Nvidia'?
'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, and has now reached every AI company in America... including Nvidia, Microsoft, and Meta.
See More aTyr Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email.

About aTyr Pharma

aTyr Pharma (NASDAQ:ATYR) engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

View aTyr Pharma Profile

More Earnings Resources from MarketBeat